Pediatrix Medical Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pediatrix Medical Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.39M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($99.07M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($60.41M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $66.34M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $130.96M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | ($64.30M) | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | ($41.04M) | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | ($672.44M) | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | ($18.71M) | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $9.33M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.81M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($68.71M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $7.32M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $172.69M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $202.92M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $32.31M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $20.46M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $34.57M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $10.80M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $40.14M | Feb 18, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $271.09M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $206.57M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $137.33M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $166.94M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $76.74M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $204.62M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $357.71M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $313.71M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $511.38M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $443.78M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.25B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.15B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.22B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.35B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $2.72B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.35B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $4.15B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $5.94B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $5.87B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $5.34B | Feb 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.38B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.37B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.46B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.83B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.60B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.65B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $2.85B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $2.80B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.58B | Feb 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $865.85M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $764.94M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $849.06M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $891.63M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $896.49M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $747.49M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.50B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $3.09B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $3.07B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.76B | Feb 14, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.24B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.38B | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | $1.53B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.51B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.48B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.48B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $4.06B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $4.28B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $3.85B | Feb 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.15M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($248.54M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($149.47M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($89.06M) | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | ($155.39M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | ($286.35M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $510.13M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $2.09B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $2.05B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.79B | Feb 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $375.24M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $229.94M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $73.26M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $9.82M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $387.39M | Feb 17, 2023 |
| FY2022 | Dec 31, 2020 | $1.12B | Feb 17, 2023 |
| FY2022 | Dec 31, 2019 | $107.87M | Feb 17, 2023 |
| FY2021 | Dec 31, 2018 | $40.77M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $40.45M | Feb 18, 2021 |
| FY2017 | Dec 31, 2016 | $55.70M | Feb 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $611.20M | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | $622.20M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $637.20M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $989.70M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.70B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.70B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.97B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.85B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.70B | Feb 14, 2018 |
| FY2016 | Dec 31, 2015 | $1.27B | Feb 10, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | (8) | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | (8) | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 82.98M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 85.87M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 84.02M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 82.95M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 86.42M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | 85.59M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 84.25M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 87.82M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | 93.72M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | 93.72M | Feb 14, 2018 |